Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to
2020
Published on October 2011

Report Summary

Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, ' Alimta (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020' provides Alimta sales
forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales,
competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes
information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalData's
proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and
featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by
GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Alimta including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Alimta including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2004-2020 for Alimta in the US, EU-5, Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020 (From Slideshare) Page 1/6


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Report Guidance 8
3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12
5 Alimta 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 As second-line treatment in comparison with Docetaxel 15
5.3.2 As first-line treatment in comparison with Gemcitabine 15
5.3.3 As maintenance therapy 16
5.4 Approval History of Alimta 17
5.5 Factors Affecting Sales of Alimta 17
5.5.1 NSCLC Market 17
5.5.2 High Overall Survival 17
5.5.3 Maintenance Therapy 17
5.5.4 Low Annual Cost of Treatment 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 18
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 19
5.8.1 Target patient Pool of Alimta 19
5.8.2 Dosing 20
5.8.3 Market Penetration 20
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Alimta 20
6 NSCLC Market: Appendix 30
6.1 Market Definitions 30
6.2 List of Abberiviations 30
6.3 Research Methodology 30



6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 34
6.5 Disclaimer 34
6.6 Sources 34

1.1 List of Tables

Table 1: NSCLC, Incidences and Mortality, 2008'2030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 2009'2020 9
Table 3: Clinical Trial Results (second-line treatment) 15
Table 4: Clinical Trial Results (first-line treatment) 16
Table 5: Clinical Trial Results (Maintenance treatment) 16
Table 6: Approval History of Alimta 17
Table 7: Drug Risk Benefit Score of Alimta 18
Table 8: Annual Cost of Therapy 20
Table 9: Alimta, NSCLC, Global, Estimated Sales ($m), 2004'2020 21
Table 10: Alimta, NSCLC, The US, Estimated Sales ($m), 2004'2020 22
Table 11: Alimta, NSCLC, The UK, Estimated Sales ($m), 2004'2020 23
Table 12: Alimta, NSCLC, France, Estimated Sales ($m), 2004'2020 24
Table 13: Alimta, NSCLC, Germany, Estimated Sales ($m), 2004'2020 25
Table 14: Alimta, NSCLC, Italy, Estimated Sales ($m), 2004'2020 26
Table 15: Alimta, NSCLC, Spain, Estimated Sales ($m), 2004'2020 27
Table 16: Alimta, NSCLC, Japan, Estimated Sales ($m), 2004'2020 28

1.2 List of Figures

Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 2009'2020 9
Figure 7: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 8: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Alimta 19
Figure 13: Alimta, NSCLC, Global, Estimated Sales ($m), 2004-2020 21
Figure 14: Alimta, NSCLC, The US, Estimated Sales ($m), 2004-2020 22



Figure 15: Alimta, NSCLC, The UK, Estimated Sales ($m) , 2004-2020 23
Figure 16: Alimta, NSCLC, France, Estimated Sales ($m), 2004-2020 24
Figure 17: Alimta, NSCLC, Germany, Estimated Sales ($m) , 2004-2020 25
Figure 18: Alimta, NSCLC, Italy, Estimated Sales ($m), 2004-2020 26
Figure 19: Alimta, NSCLC, Spain, Estimated Sales ($m),2004-2020 27
Figure 20: Alimta, NSCLC, Japan, Estimated Sales ($m), 2009-2020 28
Figure 21: Alimta, NSCLC, the US, EU 5 and Japan, Sales Distribution, 2020 29
Figure 22: GlobalData Methodology 30
Figure 23: Drug Model Diagram 32
Figure 24: Patients Approved for the Drug 32


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020

Recomendados

Recomendados

Más contenido relacionado

Destacado

Destacado (16)

Más de ReportLinker.com

Más de ReportLinker.com (20)

Alimta (Non Small Cell Lung Cancer) ' Analysis and Forecasts to 2020